Name
subinfo_valvular_heart_disease
Label
Subinfo: Participant has primary hemodynamically-significant uncorrected valvular heart disease (obstructive or regurgitant) or any valvular disease expected to require surgery during the trial
Domain
yesnof
  • 1: Yes
  • 2: No
Type
choices
Subinfo: Participant has primary hemodynamically-significant uncorrected valvular heart disease (obstructive or regurgitant) or any valvular disease expected to require surgery during the trial vs LOFT-HF Study Timepoint
Screening Visit Baseline Visit 6-Month Visit 12-Month Visit Follow-up On Treatment
Total 174 98 76 41 34
Yes - - - - -
No 98 - - - -
Unknown 76 98 76 41 34
Subinfo: Participant has primary hemodynamically-significant uncorrected valvular heart disease (obstructive or regurgitant) or any valvular disease expected to require surgery during the trial vs Subinfo: Randomization Assignment
Screening Visit
Sham treatment (room air) Active treatment (oxygen) Total
Total 50 48 98
Yes - - -
No 50 48 98
Subinfo: Participant has primary hemodynamically-significant uncorrected valvular heart disease (obstructive or regurgitant) or any valvular disease expected to require surgery during the trial vs Subinfo: Sex
Screening Visit
Male Female Total
Total 75 23 98
Yes - - -
No 75 23 98
Subinfo: Participant has primary hemodynamically-significant uncorrected valvular heart disease (obstructive or regurgitant) or any valvular disease expected to require surgery during the trial vs Subinfo: Race
Screening Visit
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White or Caucasian Other Total
Total 1 - - 28 66 3 98
Yes - - - - - - -
No 1 - - 28 66 3 98